Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

ErepoXen increases hemoglobin levels to therapeutic range in phase II trial

July 16, 2015

Merck & Co. divulges ROMK channel blockers

July 15, 2015

Aquinox Pharmaceuticals reports data from LEADERSHIP trial

June 26, 2015

Eppin Pharma receives NIH grant to develop non-hormonal male contraceptive

June 19, 2015

Angion Biomedica to begin phase II trial of BB3 in acute kidney injury

June 10, 2015

Regulus Therapeutics starts phase I trial of Alport syndrome candidate RG-012

June 5, 2015

Galenica to commercialize Roche's Mircera in U.S.

May 29, 2015

Jinarc approved in Europe for autosomal dominant polycystic kidney disease

May 28, 2015

ZS Pharma seeks U.S. approval of ZS-9 for hyperkalemia

May 27, 2015

Daiichi Sankyo develops phosphate transporter inhibitors

May 22, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...